comparemela.com
13
14
15
16
17
18
19
Latest Breaking News On - Geoff meacham - Page 12 : comparemela.com
Pfizer (PFE) Q4 2023 Earnings Call Transcript
PFE earnings call for the period ending December 31, 2023.
France
Germany
China
Japan
Australia
Canada
Kerry-holford
Chris-shibutani-goldman-sachs
David-risinger-leerink
Akash-tewari
Akash-tewari-jefferies
Terence-flynn-morgan-stanley
Hold Rating on DuPont de Nemours Amidst Earnings Shortfall and Uncertain Recovery
Vincent Andrews, an analyst from Morgan Stanley, maintained the Hold rating on DuPont de Nemours (DD – Research Report). The associated pr.
China
Vincent-andrews
Geoff-meacham
Morgan-stanley
Dupont-de-nemours
Research-report
Tipranks-premium
Freeport-McMoRan: A Strong Copper Contender Weighed by Costs and Valuation Concerns
Lawson Winder, an analyst from Bank of America Securities, maintained the Hold rating on Freeport-McMoRan (FCX – Research Report). The ass.
United-states
America
Geoff-meacham
Lawson-winder
America-securities
Research-report
Tipranks-premium
Zepbound is off to a strong start, but here's what Eli Lilly investors are watching
Investors will be tuning into the company's fourth quarter earnings call on Feb. 6, eager to hear more about how the rollout of Zepbound is going.
United-states
America
Goldman-shibutani
Geoff-meacham
Chris-shibutani
Lilly-mounjaro
Eli-lilly
Terence-flynn
Goldman-sachs
Novo-nordisk
Drug-administration-on-nov
Morgan-stanley
Endava: Hold Rating Justified by Mixed Sector Performance and Anticipated Deal Flow Amidst Valuation Concerns
Endava (DAVA – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst James Faucette from .
Geoff-meacham
James-faucette
Morgan-stanley
Research-report
Wall-street
Tipranks-premium
vimarsana © 2020. All Rights Reserved.